NanoNewron in the News

NanoNewron Files Patents Covering Use of NewroBus Technology for a Variety of Neurodegenerative Conditions

December 16th, 2024, Union, New Jersey. NanoNewron is focused on the delivery of biologicals to the brain with a lead therapeutic product (NN-841) targeting TNF-α in AD patients. Patent applications have been filed.

Scroll to Top